Christian Siso

Christian Siso

Auto-generated profile, based on publicly available information

Christian Siso

11Vall d’Hebron University Hospital, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2022 in The Lancet Global Health
Verified
Journal Article
Open access
CSCatherine A Shaw
Catherine A Shaw
RPRiinu Pius
Riinu Pius
TDThomas M Drake
Thomas M Drake
LNLisa Norman
Lisa Norman
AAAdesoji O Ademuyiwa
Adesoji O Ademuyiwa
JLJean Wilguens Lartigue
Jean Wilguens Lartigue
Early death after cancer surgery is higher in low-income and middle-income countries (LMICs) compared with in high-income countries, yet the impact of facility characteristics on early postoperative outcomes is unknown. The aim of this study was to examine the association between hospital infrastructure, resource availability, and processes on early outcomes after cancer surgery worldwide. A multimethods analysis was performed as part of the GlobalSurg 3 study—a multicentre, international, prospective cohort study of patients who had surgery for breast, colorectal, or gastric cancer. The primary outcomes were 30-day mortality and 30-day major complication rates. Potentially beneficial hospital facilities were identified by variable selection to select those associated with 30-day mortality. Adjusted outcomes were determined using generalised estimating equations to account for patient characteristics and country-income group, with population stratification by hospital. Between April 1, 2018, and April 23, 2019, facility-level data were collected for 9685 patients across 238 hospitals in 66 countries (91 hospitals in 20 high-income countries; 57 hospitals in 19 upper-middle-income countries; and 90 hospitals in 27 low-income to lower-middle-income countries). The availability of five hospital facilities was inversely associated with mortality: ultrasound, CT scanner, critical care unit, opioid analgesia, and oncologist. After adjustment for case-mix and country income group, hospitals with three or fewer of these facilities (62 hospitals, 1294 patients) had higher mortality compared with those with four or five (adjusted odds ratio [OR] 3·85 [95% CI 2·58–5·75]; p<0·0001), with excess mortality predominantly explained by a limited capacity to rescue following the development of major complications (63·0% vs 82·7%; OR 0·35 [0·23–0·53]; p<0·0001). Across LMICs, improvements in hospital facilities would prevent one to three deaths for every 100 patients undergoing surgery for cancer. Hospitals with higher levels of infrastructure and resources have better outcomes after cancer surgery, independent of country income. Without urgent strengthening of hospital infrastructure and resources, the reductions in cancer-associated mortality associated with improved access will not be realised. National Institute for Health and Care Research.

22 May 2023 in European Journal of Surgical Oncology
Verified
Journal Article
Open access
CSChristian Siso
Christian Siso
AEAntonio Esgueva
Antonio Esgueva
JRJoaquin Rivero
Joaquin Rivero
CMClara Morales
Clara Morales
IMIgnacio Miranda
Ignacio Miranda
IRIsabel Teresa Rubio
Isabel Teresa Rubio
Axillary management in cN + axillary nodes after neoadjuvant systemic therapy (NST) in breast cancer (BC) remains under research with the aim of de-escalation of axillary node dissection (ALND). Several axillary guided localization techniques have been reported. This study evaluates the safety of intraoperative ultrasound (IOUS) guided targeted axillary dissection (TAD) in a large sample after the results of ILINA trial. Prospective data have been collected from October 2015 to June 2022 in patients with cT0-T4 and positive axillary lymph nodes (cN1) treated with NST. Before NST, an ultrasound visible marker was placed into the positive node. After NST, IOUS guided TAD was performed including sentinel node biopsy (SLN). Until December 2019, all patients underwent an ALND after TAD procedure. From January 2020, ALND was spared in those patients with an axillary pathological complete response (pCR). 235 patients were included. pCR (ypT0/is ypN0) was achieved in 29% patients. Identification rate (IR) of the clipped node by IOUS was 96% (95% IC, 92.5-98.1%) and IR of SLN was 95% (95% IC, 90.8-97.2%). False negative rate (FNR) for TAD procedure (SLN + clipped node) was 7.0% (95% IC, 2.3-15.7%), which decreased to 4.9% when a total of 3 or more nodes were removed. Axillary ultrasound before surgery assessed residual disease with an AUC of 0.5241. Residual axillary disease tend to be the most significant factor for axillary recurrences. This study confirms the feasibility, safety and accuracy of IOUS guided surgery for axillary staging after NST in node positive BC patients.

16 January 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
MVMaría Jesus Vidal
María Jesus Vidal
CFClaudette Falato
Claudette Falato
TPTomas Pascual
Tomas Pascual
RSRodrigo Sánchez-Bayona
Rodrigo Sánchez-Bayona
MMMontserrat Muñoz-Mateu
Montserrat Muñoz-Mateu
Meritxell BelletMeritxell Bellet
Meritxell Bellet
Purpose: Elacestrant has shown significantly prolonged progression-free survival compared with standard-of-care endocrine therapy in estrogen receptor–positive (ER-positive), HER2-negative metastatic breast cancer, whereas potential benefit in early-stage disease requires further exploration. The SOLTI-ELIPSE window-of-opportunity trial investigated the biological changes induced by a short course of preoperative elacestrant in postmenopausal women with early breast cancer. Patients and Methods: Eligible patients with untreated T1c (≥1.5 cm)-T3, N0, ER-positive/HER2-negative breast cancer with locally assessed Ki67 ≥10% received elacestrant at a daily dose of 345 mg for 4 weeks. The primary efficacy endpoint was complete cell cycle arrest, defined as Ki67 ≤2.7%, on day 28. Results: Overall, 22 patients were evaluable for the primary endpoint. Elacestrant was associated with a complete cell cycle arrest rate of 27.3% and a statistically significant Ki67 geometric mean change of −52.9% (P = 0.007; 95% confidence interval, −67.4 to −32.1). Notably, the treatment with elacestrant led to a shift toward a more endocrine-sensitive and less proliferative tumor phenotype based on PAM50-based gene signatures. Elacestrant increased the expression of immune-response genes (GZMB, CD4, and CD8A) and suppressed proliferation and estrogen-signaling genes (MKI67, ESR1, and AR). These biological changes were independent of the levels of Ki67 suppression on day 28. The most common adverse events were grade 1 anemia (21.7%), hot flushes (8.7%), constipation (8.7%), and abdominal pain (8.7%). One patient experienced a grade 3 cutaneous rash, leading to treatment discontinuation. No other serious adverse events were reported. Conclusions: Preoperative treatment with elacestrant in early breast cancer demonstrated relevant biological and molecular responses and exhibited a manageable safety profile. These findings support further investigation of elacestrant in the early setting.

1 April 2025
Verified
Other
Open access
PDF file
MVMaría Jesus Vidal
María Jesus Vidal
CFClaudette Falato
Claudette Falato
TPTomas Pascual
Tomas Pascual
RSRodrigo Sánchez-Bayona
Rodrigo Sánchez-Bayona
MMMontserrat Muñoz-Mateu
Montserrat Muñoz-Mateu
Meritxell BelletMeritxell Bellet
Meritxell Bellet
Supplementary Figure S1. Clinical trial design of the ELIPSE trial.

1 April 2025
Verified
Other
Open access
PDF file
MVMaría Jesus Vidal
María Jesus Vidal
CFClaudette Falato
Claudette Falato
TPTomas Pascual
Tomas Pascual
RSRodrigo Sánchez-Bayona
Rodrigo Sánchez-Bayona
MMMontserrat Muñoz-Mateu
Montserrat Muñoz-Mateu
Meritxell BelletMeritxell Bellet
Meritxell Bellet
Supplementary Table S4. Preoperative trials evaluating Ki67 changes during and/or after endocrine therapy (with or without targeted therapy) in hormone receptor-positive and HER2-negative early breast cancer.

1 April 2025
Verified
Other
Open access
PDF file
MVMaría Jesus Vidal
María Jesus Vidal
CFClaudette Falato
Claudette Falato
TPTomas Pascual
Tomas Pascual
RSRodrigo Sánchez-Bayona
Rodrigo Sánchez-Bayona
MMMontserrat Muñoz-Mateu
Montserrat Muñoz-Mateu
Meritxell BelletMeritxell Bellet
Meritxell Bellet
Supplementary Figure S4. Volcano plots showing the differential baseline gene expression according to response to elacestrant based on post-treatment Ki67 (day 28) in: A) sensitive tumors and B) resistant tumors.